Acumen Pharmaceuticals/$ABOS
1D1W1MYTD1Y5YMAX
About Acumen Pharmaceuticals
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
- Ticker
- $ABOS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 61
- Headquarters
- Newton, United States
- Website
- acumenpharm.com
ABOS Metrics
BasicAdvanced
$198M
-
-$1.64
0.33
-
Price and volume
Market cap
$198M
Beta
0.33
52-week high
$3.60
52-week low
$1.21
Average daily volume
355K
Financial strength
Current ratio
2.466
Quick ratio
2.352
Long term debt to equity
20.774
Total debt to equity
55.264
Interest coverage (TTM)
-24.41%
Profitability
EBITDA (TTM)
-105.367
Management effectiveness
Return on assets (TTM)
-45.77%
Return on equity (TTM)
-120.50%
Valuation
Price to book
3.46
Price to tangible book (TTM)
3.46
Price to free cash flow (TTM)
-1.915
Free cash flow yield (TTM)
-52.21%
Free cash flow per share (TTM)
-1.43
Growth
Earnings per share change (TTM)
-27.75%
3-year earnings per share growth (CAGR)
12.75%
What the Analysts think about ABOS
Analyst ratings (Buy, Hold, Sell) for Acumen Pharmaceuticals stock.
ABOS Financial Performance
Revenues and expenses
ABOS Earnings Performance
Company profitability
ABOS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.